As surgical teams in the US face mounting pressure to reduce costs, avoid complications, and improve patient outcomes, a new generation of medtech startups is stepping in with data-driven tools. One of the most promising is Insight Surgery, a UK-founded company that has just secured $2.5 million in Series A funding to expand its personalized surgery platform across American hospitals.
Led by Nodenza Venture Partners, the investment comes on the heels of FDA 510(k) clearance for Insight’s bespoke surgical guides, which are designed to help surgeons plan operations with unprecedented accuracy. These 3D-printed guides, made from advanced materials like LaserForm Ti and DuraForm ProX PA, are not only 20 times stronger than traditional versions—they’re also 70% thinner, improving surgical access and cutting down time in the operating room.
The economic case is clear: each extra hour in surgery adds thousands of dollars in costs. Clinical studies have shown that Insight’s guides can reduce operating time by an average of 23 minutes per procedure. In a healthcare system where nearly one in seven patients is readmitted within 30 days of surgery, this matters.
With this funding, Insight plans to expand its US operations by opening two new manufacturing hubs—one on each coast—while doubling its headcount and ramping up partnerships with hospitals. The company’s longer-term vision includes broadening its focus from orthopaedics into oncology and maxillofacial surgery, where surgical precision is just as vital.
How the Insight Surgery Personalized Surgery Platform Works
Insight Surgery’s EmbedMed platform transforms patient scan data into detailed surgical planning models and produces tailored 3D-printed guides. Surgeons can simulate procedures in advance and receive physical guides within 10 working days—often much faster than industry standards.
Founded by CEO Henry Pinchbeck, a Cambridge-trained entrepreneur, and biomedical engineer Peter Tofield, Insight was born from their shared experience commercialising healthcare innovations in the UK. The company’s mission is to make personalised surgical planning accessible, scalable, and cost-effective. Their platform is already in use at top-tier hospitals including the Hospital for Special Surgery (NY), University Hospitals of Chicago, and University of Florida Health.
Unlike other players such as Materialise or 3D Systems, Insight has built a vertically integrated model, with its own FDA-registered and ISO 13485-certified facility inside the Texas Medical Center in Houston. This enables the company to move quickly from data to device, improving both turnaround time and feedback loops from surgeons in the field.
The personalized surgery space is projected to grow rapidly—surgical planning software alone is expected to more than double in size over the next decade. Meanwhile, the 3D-printed surgical guide market is forecast to hit $9.5 billion by 2032. Insight’s ability to deliver fast, precise, and economically sound solutions positions it well in this expanding market.
Dr. Adam Levine, a musculoskeletal oncology surgeon, underscored the platform’s clinical value: “Insight’s guides enable me to operate faster and more accurately, leading to fewer complications, faster recovery, and better patient outcomes. It’s one of the few surgical innovations that’s both clinically and financially compelling.”
